On September 20, 2021 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, reported that it will present at four upcoming investor conferences (Press release, Actinium Pharmaceuticals, SEP 20, 2021, View Source [SID1234587955]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sandesh Seth, Actinium’s Chairman and CEO, said, "Having recently completed enrollment of our pivotal Phase 3 trial for Iomab-B, we look forward to highlighting multiple upcoming milestones in the fourth quarter from our targeted radiotherapy pipeline including SIERRA data updates, updates from our novel Actimab-A combination trials and new programs arising from our AWE technology platform to a broad audience of investors. We are excited to finish 2021 with strong momentum as we look ahead to 2022 when we will present topline data from SIERRA."

Cantor Fitzgerald Global Healthcare Conference
September 27th – 30th

Benzinga Healthcare Conference
September 30th

BioFuture
October 5th – 6th

Alliance Global Partners Virtual Biotech & Specialty Pharma Conference
October 13th

Information about Actinium’s presentation at these conferences will be available on the investor relations page of Actinium’s website at www.actiniumpharma.com.